Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome
Go back to Anavex Life Sciences Receives Positive Opinion for Orphan Designation from the European Medicines Agency for ANAVEX®2-73 for the Treatment of Rett Syndrome| Anavex Life Sciences Corp. (NASDAQ: AVXL) | Delayed: 2.50 +0.04 (1.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.46 | 52 Week High | $8.30 | |||
| Open | $2.44 | 52 Week Low | $2.43 | |||
| Day High | $2.52 | P/E | N/A | |||
| Day Low | $2.41 | EPS | $-0.22 | |||
| Volume | 469,158 | |||||
